Benzinga | Jul 13, 2020 12:08PM EDT

B of A Securities Maintains Buy on bluebird bio, Lowers Price Target to $100

B of A Securities analyst Jason Gerberry maintains bluebird bio (NASDAQ:BLUE) with a Buy and lowers the price target from $104 to $100.